Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omegaven with Chemotherapy in High-Risk AML
NCT01999413Phase 2Completed
- Sponsor
- French Innovative Leukemia Organisation
- Start
- Nov 2013
- Primary completion
- Mar 2016
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of eicosapentaenoic acid + docosahexaenoic acid in acute myeloid leukemia (AML), sponsored by French Innovative Leukemia Organisation. Primary endpoint: Response to study treatment at 1 month. Started Nov 2013; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01999413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01999413.